AAADV not only impacts the rate at which oncology drugs are brought to market, but patients afflicted with cancer have been able to appreciate significant advances in their care and survival rates.
Director, Office of Hematology and Oncology Drug Products
U.S. Food and Drug Administration Center for Drug Evaluation and Research
Leaders in clinical and translational cancer research from academia, industry, government and the nonprofit advocacy sector focus on understanding and efficiently negotiating the drug development process.
May 4-6, 2016